跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
CINQAIR reslizumab 100 mg/10 mL concentrated solution for intravenous infusion vial
Approved
STANDARD
CINQAIR reslizumab 100 mg/10 mL concentrated solution for intravenous infusion vial
Teva Pharma Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
9b79a704a4662e01
Company
Teva Pharma Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
9b79a704a4662e01
Product Name
CINQAIR reslizumab 100 mg/10 mL concentrated solution for intravenous infusion vial
Artg Id
277278
Artg Name
CINQAIR reslizumab 100 mg/10 mL concentrated solution for intravenous infusion vial
Sponsor
Teva Pharma Australia Pty Ltd
Company Detail Path
/organization/teva-pharma-australia-pty-ltd
Artg Date
2017-07-25
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
9b79a704a4662e01
Type
Standard
Back to TGA Approvals
CINQAIR reslizumab 100 mg/10 mL concentrated solution for intravenous infusion vial - TGA Drug Approval Details
